Dyax Corp. (NASDAQ:DYAX) CMO Burt A. Adelman sold 55,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $9.68, for a total transaction of $532,400.00. Following the transaction, the chief marketing officer now directly owns 37,500 shares in the company, valued at approximately $363,000. Dyax Corp. (NASDAQ:DYAX) shares fell -9.11% in last trading session and ended the day on $9.23. DYAX return on equity ratio is recorded as 101.70% and its return on assets is -34.40%. Dyax Corp. (NASDAQ:DYAX) yearly performance is 126.23%.
Omeros Corporation (NASDAQ:OMER) announced its intention to offer, subject to market and other conditions, shares of its common stock in a registered underwritten public offering. Omeros also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover overallotments, if any. Omeros Corporation (NASDAQ:OMER) shares moved down -7.72%in last trading session and was closed at $11.35, while trading in range of $11.00 – $11.59. Omeros Corporation (NASDAQ:OMER) year to date (YTD) performance is 0.53%.
Tesaro Inc (NASDAQ:TSRO) had its price objective hosited by Deutsche Bank to $72.00 in a report released on Thursday, Analyst Ratings Network reports. TESARO Inc (NASDAQ:TSRO) weekly performance is 21.88%. On last trading day company shares ended up $36.76. TESARO Inc (NASDAQ:TSRO) distance from 50-day simple moving average (SMA50) is 18.34%. Analysts mean target price for the company is $44.14.
Equities researchers at Needham & Company LLC assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report issued on Thursday, Analyst Ratings Network.com reports. The firm set a “buy” rating on the stock. Cara Therapeutics Inc (NASDAQ:CARA) shares after opening at $18.22 on last trade day and at the end of the day closed at $17.26. Company price to sales ratio in past twelve months was calculated as 34.27 and price to cash ratio as 21.30. Cara Therapeutics Inc (NASDAQ:CARA) showed a negative weekly performance of -13.70%.